Skip to main content
Top
Published in: Clinical and Experimental Nephrology 2/2011

01-04-2011 | Case Report

A rare case of malignant-phase hypertension with pulmonary alveolar hemorrhage

Authors: Kazutaka Nanba, Kensei Yahata, Yuko Kikuchi, Chinatsu Okamoto, Koichi Seta, Akira Sugawara

Published in: Clinical and Experimental Nephrology | Issue 2/2011

Login to get access

Abstract

Malignant-phase hypertension is characterized clinically by severe accelerating hypertension with neuroretinopathy or papilledema and by evidence of renal damage. A Japanese male in his early thirties presented with hemoptysis and general fatigue. He had a 5-year history of hypertension, but had not received any treatment. His blood pressure was 290/150 mmHg and his serum creatinine level was 8.24 mg/dL. Chest X-rays and computed tomography scans of the chest revealed a pulmonary alveolar hemorrhage. He was suspected of having vasculitis syndrome or Goodpasture’s syndrome, but his renal biopsy specimen showed malignant nephrosclerosis. Myeloperoxidase antineutrophil cytoplasmic antibody (ANCA), proteinase-3 ANCA and antiglomerular basement membrane antibody were negative. He was treated with a calcium antagonist and a β-blocker, followed by an angiotensin-converting enzyme inhibitor. After the administration of the β-blocker, his blood pressure decreased and his renal function gradually improved. This is a rare case of malignant-phase hypertension with pulmonary alveolar hemorrhage; this condition should be considered in the differential diagnosis in order to avoid unnecessary treatment such as immunosuppressive therapy.
Literature
1.
go back to reference Lip GY, Beevers M, Beevers DG. Complications and survival of 315 patients with malignant-phase hypertension. J Hypertens. 1995;13:915–24.PubMedCrossRef Lip GY, Beevers M, Beevers DG. Complications and survival of 315 patients with malignant-phase hypertension. J Hypertens. 1995;13:915–24.PubMedCrossRef
2.
go back to reference Sesoko S, Akema N, Matsukawa T, Kaneko Y. Predisposing factors for the development of malignant essential hypertension. Arch Intern Med. 1987;147:1721–4.PubMedCrossRef Sesoko S, Akema N, Matsukawa T, Kaneko Y. Predisposing factors for the development of malignant essential hypertension. Arch Intern Med. 1987;147:1721–4.PubMedCrossRef
3.
go back to reference Isles CG, Johnson AO, Milne FJ. Slow release nifedipine and atenolol as initial treatment in blacks with malignant hypertension. Br J Clin Pharmacol. 1986;21:377–83.PubMed Isles CG, Johnson AO, Milne FJ. Slow release nifedipine and atenolol as initial treatment in blacks with malignant hypertension. Br J Clin Pharmacol. 1986;21:377–83.PubMed
4.
go back to reference Mancia G, De Backer G, Dominiczak A, Cifkova R, Fagard R, Germano G, et al. 2007 Guidelines for the management of arterial hypertension: the task force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J. 2007;28:1462–536.PubMed Mancia G, De Backer G, Dominiczak A, Cifkova R, Fagard R, Germano G, et al. 2007 Guidelines for the management of arterial hypertension: the task force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J. 2007;28:1462–536.PubMed
5.
go back to reference Nakamoto H, Nemoto H, Sugahara S, Okada H, Suzuki H. Nifedipine and arotinolol in combination for accelerated-malignant hypertension: results of one year follow-up. Hypertens Res. 1999;22:75–80.PubMedCrossRef Nakamoto H, Nemoto H, Sugahara S, Okada H, Suzuki H. Nifedipine and arotinolol in combination for accelerated-malignant hypertension: results of one year follow-up. Hypertens Res. 1999;22:75–80.PubMedCrossRef
6.
go back to reference De Lassence A, Fleury-Feith J, Escudier E, Beaune J, Bernaudin JF, Cordonnier C. Alveolar hemorrhage. Diagnostic criteria and results in 194 immunocompromised hosts. Am J Respir Crit Care Med. 1995;151:157–63.PubMed De Lassence A, Fleury-Feith J, Escudier E, Beaune J, Bernaudin JF, Cordonnier C. Alveolar hemorrhage. Diagnostic criteria and results in 194 immunocompromised hosts. Am J Respir Crit Care Med. 1995;151:157–63.PubMed
7.
go back to reference Hida K, Wada J, Odawara M, Kunitomi M, Hayakawa N, Kashihara N, et al. Malignant hypertension with a rare complication of pulmonary alveolar hemorrhage. Am J Nephrol. 2000;20:64–7.PubMedCrossRef Hida K, Wada J, Odawara M, Kunitomi M, Hayakawa N, Kashihara N, et al. Malignant hypertension with a rare complication of pulmonary alveolar hemorrhage. Am J Nephrol. 2000;20:64–7.PubMedCrossRef
8.
go back to reference Sato Y, Hara S, Yamada K, Fujimoto S. A rare case of alveolar haemorrhage due to malignant hypertension. Nephrol Dial Transplant. 2005;20:2289–90.PubMedCrossRef Sato Y, Hara S, Yamada K, Fujimoto S. A rare case of alveolar haemorrhage due to malignant hypertension. Nephrol Dial Transplant. 2005;20:2289–90.PubMedCrossRef
9.
go back to reference Torra R, Poch E, Torras A, Bombi JA, Revert L. Pulmonary hemorrhage as a clinical manifestation of hemolytic-uremic syndrome associated with mitomycin C therapy. Chemotherapy. 1993;39:453–6.PubMedCrossRef Torra R, Poch E, Torras A, Bombi JA, Revert L. Pulmonary hemorrhage as a clinical manifestation of hemolytic-uremic syndrome associated with mitomycin C therapy. Chemotherapy. 1993;39:453–6.PubMedCrossRef
10.
go back to reference Piastra M, Ruggiero A, Langer A, Caresta E, Chiaretti A, Pulitano S, et al. Pulmonary hemorrhage complicating a typical hemolytic-uremic syndrome. Respiration. 2004;71:537–41.PubMedCrossRef Piastra M, Ruggiero A, Langer A, Caresta E, Chiaretti A, Pulitano S, et al. Pulmonary hemorrhage complicating a typical hemolytic-uremic syndrome. Respiration. 2004;71:537–41.PubMedCrossRef
11.
go back to reference Martinez AJ, Maltby JD, Hurst DJ. Thrombotic thrombocytopenic purpura seen as pulmonary hemorrhage. Arch Intern Med. 1983;143:1818–20.PubMedCrossRef Martinez AJ, Maltby JD, Hurst DJ. Thrombotic thrombocytopenic purpura seen as pulmonary hemorrhage. Arch Intern Med. 1983;143:1818–20.PubMedCrossRef
12.
go back to reference Srivastava A, Gottlieb D, Bradstock KF. Diffuse alveolar haemorrhage associated with microangiopathy after allogeneic bone marrow transplantation. Bone Marrow Transplant. 1995;15:863–7.PubMed Srivastava A, Gottlieb D, Bradstock KF. Diffuse alveolar haemorrhage associated with microangiopathy after allogeneic bone marrow transplantation. Bone Marrow Transplant. 1995;15:863–7.PubMed
13.
go back to reference Naniwa T, Banno S, Sugiura Y, Yokota K, Oosawa T, Maeda S, et al. Pulmonary-renal syndrome in systemic sclerosis: a report of three cases and review of the literature. Mod Rheumatol. 2007;17:37–44.PubMedCrossRef Naniwa T, Banno S, Sugiura Y, Yokota K, Oosawa T, Maeda S, et al. Pulmonary-renal syndrome in systemic sclerosis: a report of three cases and review of the literature. Mod Rheumatol. 2007;17:37–44.PubMedCrossRef
Metadata
Title
A rare case of malignant-phase hypertension with pulmonary alveolar hemorrhage
Authors
Kazutaka Nanba
Kensei Yahata
Yuko Kikuchi
Chinatsu Okamoto
Koichi Seta
Akira Sugawara
Publication date
01-04-2011
Publisher
Springer Japan
Published in
Clinical and Experimental Nephrology / Issue 2/2011
Print ISSN: 1342-1751
Electronic ISSN: 1437-7799
DOI
https://doi.org/10.1007/s10157-010-0397-6

Other articles of this Issue 2/2011

Clinical and Experimental Nephrology 2/2011 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine